一例通过下一代测序鉴定出罕见基因融合且对克唑替尼有长期反应的肺腺癌病例
A Case of Lung Adenocarcinoma Harboring a Rare Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib.
作者信息
Zhang Min, Zhou Huan, Liu Dan, Yu Ruoying, Chen Jun
机构信息
Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Department of Research and Development, Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
出版信息
JTO Clin Res Rep. 2020 Oct 17;2(2):100106. doi: 10.1016/j.jtocrr.2020.100106. eCollection 2021 Feb.
Abstract
Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.
摘要
大多数最初敏感的非小细胞肺癌患者在应用ALK抑制剂一段时间后会产生耐药性。我们在此展示了一种对克唑替尼治疗有反应的罕见基因融合；该患者实现了23个月的无进展生存期。
Zotero 插件